Background Scarce data are available on what variables affect the risk of transmission of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of …

Background Monkeypox DNA has been detected in skin lesions, saliva, oropharynx, urine,
semen, and stool of patients infected during the 2022 clade IIb outbreak; however, the viral …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments
for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many …

Background. Combination antiretroviral therapy (cART) generally suppresses the replication
of the human immunodeficiency virus type 1 (HIV-1) but does not cure the infection, …

We read with interest the recent article by Collins et al. 1 regarding under-identification of
hospital clusters of Group B Streptococcus (GBS) disease outbreaks. The first step in …

Background Myeloid cells are key players in the recognition and response of the host against
invading viruses. Paradoxically, upon HIV-1 infection, myeloid cells might also promote …

Background Mass testing for early identification and isolation of infectious COVID-19 individuals
is efficacious for reducing disease spread. Antigen-detecting rapid diagnostic tests (Ag-…

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed
to assess whether CP administered during the first week of symptoms reduced the disease …

Background: Latent HIV-1-infected cells generated early in the infection are responsible for
viral persistence, and we hypothesized that addition of maraviroc to triple therapy in patients …